Medivir—focusing on cancer one prodrug at a time

Medivir is developing tumor-directed nucleotide oral prodrugs to treat cancers with highly unmet medical needs. The company’s lead drug candidate, MIV-818, is a liver cancer targeted prodrug that Medivir is looking to develop alone in the USA and the EU and through partnerships elsewhere.

Like Comment
Page of
Go to the profile of Medivir


COO, Medivir

Medivir is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer. To do this efficiently and with a high success rate, we bring together a unique combination of clinical development skills, a collaborative culture and an extensive industry experience, with a balanced project portfolio.

No comments yet.